Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Breast-Cancer-Virtual-Meeting-1000x250

Satellite Symposia Resources from OncologyPRO sponsors

Find here all the resources from Industry Satellite Symposia published by our industry partners.

Debate-in-the-Modern-Management-of-HER2-HR+MBC-Should-Chemotherapy-be-the-Treatment-of-Last-Resort-EISAI-Thumb
Debate: In the modern management of HER2-/HR+ MBC, should chemotherapy be the treatment of last resort?

Eisai Satellite Symposium

Introduction
Presenter: Joseph Gligorov (Paris, France)

Against the Motion – Opening Remarks
Presenter: Javier Cortés (Barcelona, Spain)

For the Motion – Opening Remarks
Presenter: Peter Schmid (London, United Kingdom)

For the Motion – Closing Remarks
Presenter: Peter Schmid (London, United Kingdom)

Against the Motion – Closing Remarks
Presenter: Javier Cortés (Barcelona, Spain)

Close (Thank you)
Presenter: Joseph Gligorov (Paris, France)

Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer Thumb

Novel Therapies for Relapsed or Refractory HER2-Positive Metastatic Breast Cancer

CME Webinar supported by Daiichi Sankyo

Novel Anti-HER2-Directed ADCs
Presenter: Adam M. Brufsky (Pittsburgh, PA, United States of America)

Novel Targeted Therapies for MBC - Tyrosine kinase inhibitors
Presenter: Cristina Saura Manich (Barcelona, Spain)

Novel Anti-HER2 Monoclonal Antibody
Presenter: Thomas Bachelot (Lyon, France)

Case Discussion: Medical Need for Novel HER2-Directed Options After Failure on Standard-of-Care Treatments
Presenter: Thomas Bachelot (Lyon, France)

 

A-New-Decade-in-the-Evolving-Treatment-Landscape-for-HER2-Positive-Metastatic-Breast-Cancer-DAIICHI-SANKYO-Thumb

A New Decade in the Evolving Treatment Landscape for HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo

Welcome & introduction
Presenter: Javier Cortés (Barcelona, Spain)

Current state-of-the-art in treating HER2 positive metastatic breast cancer
Presenter: Sandra M. Swain (Washington, DC, United States of America)

What is the potential ‘Clinical Value’ of emerging therapies in HER2 metastatic breast cancer?
Presenter: Fatima Cardoso (Lisbon, Portugal)

Concluding remarks
Presenter: Javier Cortés (Barcelona, Spain)

 

The-Power-of-Choice-in-HR+-HER2-Advanced-Breast-Cancer-A-Case-Continuum-NOVARTIS-Thumb

The Power of Choice in HR+, HER2- Advanced Breast Cancer: A Case Continuum

Novartis Satellite Symposium

Welcome and introduction
Presenter: Dejan Juric (Boston, United States of America)

Introduction of the case
Presenter: Dejan Juric (Boston, United States of America)

Presentation and selection of a first-line therapy
Presenter: Fatima Cardoso (Lisbon, Portugal)

Panel discussion
Presenters: Dejan Juric (Boston, United States of America),  Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)

Spotlight presentation: Fulvestrant as combination partner in both first and second line
Presenters: Dejan Juric (Boston, United States of America),  Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)

Switching to a second-line treatment
Presenter: Hans-Christian Kolberg (Bottrop, Germany)

Panel discussion
Presenters: Dejan Juric (Boston, United States of America),  Fatima Cardoso (Lisbon, Portugal), Hans-Christian Kolberg (Bottrop, Germany)

Putting the Case in Context
Presenter: Dejan Juric (Boston, United States of America)

Panel Discussion: COVID-19 and Patient Management
Presenter: Dejan Juric (Boston, United States of America)

 

The-Evolving-Treatment-Landscape-of-Early-Triple-Negative-Breast-Cancer-MSD-Thumb

The Evolving Treatment Landscape of Early Triple Negative Breast Cancer

MSD Satellite Symposium

Introduction
Presenter: Sherko Kümmel (Essen, Germany)

Neoadjuvant versus adjuvant therapy: What to consider?
Presenter: Marc Thill (Frankfurt, Germany)

Future perspective on early TNBC: Current developments
Presenter: Frederik Marmé (Mannheim, Germany)

Panel discussion
Presenter: Sherko Kümmel (Essen, Germany)

Summary and Conclusion
Presenter: Sherko Kümmel (Essen, Germany)

 

Optimising-breast-cancer-outcomes-Clinical-and-real-world-experience-lead-to-strength-in-numbers-PFIZER-Thumb

Optimising breast cancer outcomes: Clinical and real-world experience lead to strength in numbers

Pfizer Satellite Symposium

What can real-world evidence do for metastatic breast cancer?
Presenter: Nadia Harbeck (Munich, Germany)

From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment
Presenter: Nadia Harbeck (Munich, Germany)

From p-values to patient-centricity: refining our approach to metastatic breast cancer treatment
Presenter: Hope S. Rugo (San Francisco, CA, United States of America)

Emerging therapies in breast cancer: will more options lead to improved outcomes?
Presenter: Nadia Harbeck (Munich, Germany)

 

How-to-do-more-to-improve-HER2-positive-early-breast-cancer-patient-outcomes-PIERRE-FABRE-Thumb

How to do more to improve HER2- positive early breast cancer patient outcomes?

Pierre Fabre Satellite Symposium

Welcome and introductions
Presenter: Joseph Gligorov (Paris, France)

Sizing the unmet need in the treatment of early HER2-positive breast cancer
Presenter: Michael Untch (Berlin, Germany)

Optimizing the use of neratinib in the extended adjuvant setting
Presenter: Miguel Martin Jimenez (Madrid, Spain)

Patients stories : one more step to cure
Presenter: Michelino De Laurentiis (Naples, Italy)

Conclusive remarks
Presenter: Joseph Gligorov (Paris, France)

 

Bringing-Molecular-Insights-to-The-Clinic-Recent-Advances-in-Breast-Cancer-Treatment-ROCHE-Thumb

Bringing molecular insights to the clinic: recent advances in Breast Cancer treatment

Roche Satellite Symposium

Welcome and Introduction
Presenter: Rebecca Dent (Singapore, Singapore)

FOUNDATION – Key Recent Advances in Understanding Breast Cancer Biology and Their Contribution to the Development of Targeted Treatments
Presenter: Giampaolo Bianchini (Milan, Italy)

CURRENT CLINICAL IMPLICATIONS – Translating Recent Molecular Biology Insights into Today’s Clinical Practice
Presenter: Sherko Kümmel (Essen, Germany)

FUTURE INSIGHTS – How Will Emerging Technologies Shape the Future of Breast Cancer Care?
Presenter: Rebecca Dent (Singapore, Singapore)

Key Insights and Conclusions
Presenter: Rebecca Dent (Singapore, Singapore)

 

Improving-Outcomes-After-T-DM1-A-A-New-Horizon-for-HER2+-mBC-Patients-SEATTLE-GENETICS-Thumbs

Improving outcomes after T-DM1 A new horizon for HER2+ mBC patients

Seattle Genetics Satellite Symposium

Chair’s Welcome 
Presenter: Alicia Okines (London, United Kingdom)

Shifting paradigms in HER2+ mBC with new treatment approaches
Presenter: Cristina Saura Manich (Barcelona, Spain)

New frontiers in the management of HER2+ brain metastases
Presenter: Thomas Bachelot (Lyon, France)

Data discussion and impact on patients
Presenters: Alicia Okines (London, United Kingdom), Thomas Bachelot (Lyon, France), Cristina Saura Manich (Barcelona, Spain)

Conclusions
Presenter: Alicia Okines (London, United Kingdom)

 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings